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Folate and homocysteine metabolisms and their roles in the biochemical
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Abstract: The term ‘one-carbon metabolism’ is commonly used to describe 3 separate metabolic processes: folate metabolism, the
homocysteine remethylation cycle, and the transsulfuration pathway. Folate metabolism concerns the biochemical reactions in which
endogenous and exogenous one-carbon units are transferred to tetrahydrofolates. The remethylation cycle is used for the synthesis of
methionine from homocysteine with one-carbon units that come from folate. This methionine is then used for the synthesis of S-adenosyl
methionine, which is a general donor of methyl groups for many biochemical reactions in the human body. In the transsulfuration
pathway, some amino acids and polypeptides, such as cystathionine, cysteine, and glutathione, are synthesized from homocysteine. The
kinetics of the enzymes in this pathway are regulated by the substrates of the remethylation cycle. The methylation process has been
thought to have an important role in the biochemical basis of neuropsychiatry. An elevated homocysteine level is the most important
marker of folate and vitamin B12 deficiencies, and also the most reliable biochemical sign of functional insufficiency. Some neurological
and neuropsychiatric diseases, such as psychosis, Alzheimer’s disease, and autism, have been found to be related to disorders of onecarbon metabolism. This review aims to summarize both one-carbon metabolism and its relationships with neuropsychiatric disorders.
Key words: One-carbon metabolism, folic acid, folate subgroups, homocysteine, vitamin B12, neuropsychiatric disorders

1. Introduction
When considering its relations with many biochemical
reactions and its roles in some essential metabolisms,
disorders or imbalances of the one-carbon metabolism
may result in wide ranges of disorders that affect human
health, particularly in neuropsychiatric and cardiovascular
areas.
Folate metabolism is one of the basic metabolisms of
biochemistry in which one-carbon units are transferred to
homocysteine, as well as purine-pyrimidine nucleotides
and some amino acids are synthesized. Homocysteine
is a molecule that stands at the junction point of the
remethylation cycle and the transsulfuration pathway.
Understanding biochemistry, regulations, and
relationships of one-carbon metabolism could encourage
researchers to investigate the neuropsychiatric disorders
through performing advanced studies that produce
valuable findings elucidating the causal and molecular
basis of the pathogenesis.
Because they provide detoxification of homocysteine,
the remethylation cycle and the transsulfuration pathway
together can be evaluated as ‘homocysteine metabolism’.
* Correspondence: alpaslancosar@yahoo.com.

Hence, one-carbon metabolism will be explained under 2
titles: folate and homocysteine metabolisms.
2. Folate and its metabolism
2.1. Folic acid
Folic acid is a water-soluble vitamin from the B group
(vitamin B9), which is also referred to as folate and pteroyl
monoglutamate (PteGlu). Its chemical structure consists
of 3 parts: a pteridine ring, paraaminobenzoic acid, and
glutamic acid (Figure 1). Natural folates are classified
according to the oxidation state of the pteridine ring, the
nature of the one-carbon units at the N5 and N10 positions,
and the number of glutamic acid residues.
2.2. Dietary sources and absorption
Humans cannot synthesize folic acid and thus are dependent
on dietary sources. Yeast extracts, liver, kidney, leafy green
vegetables, and citrus fruits are folate-rich foods. Bread,
potatoes, and dairy products are middle-grade sources,
but because they are consumed in large quantities, they
contribute significantly to total folate intake (1). Folates
in foods are transported via an ion-exchange mechanism
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Figure 1. Chemical structure of folic acid.

that is carried out against the pH gradient along the brush
membrane of enterocytes. Folate is anionic at intraluminal
pH and it is exchanged with a hydroxyl anion. Although
absorption is higher proximally, it is absorbed all along
the jejunum. Polyglutamyl folates are hydrolyzed into
monoglutamyl folates by gamma-glutamyl hydrolase
(GGH) and then all monoglutamyl folates are converted
into 5-methyltetrahydrofolate-monoglutamate (5-MTHFGlu1) in enterocytes. 5-MTHF-Glu1 is the plasma form of
this vitamin and it is transported to the peripheral tissues,
where it is converted into tetrahydrofolate-monoglutamate
(THF-Glu1) via a reaction catalyzed by methionine
synthase that uses vitamin B12 as a cofactor (2).
2.3. Folate transport
2.3.1. Transport in plasma
After absorption, 5-MTHF-Glu1 enters the portal
circulation. The liver takes up most of this folate and some
of it is released into the enterohepatic cycle by secretion
into the bile. The plasma concentration of 5-MTHFGlu1 is 3–30 ng/mL. In short-term folic acid deficiency,
folylmonoglutamate pools in cells and the enterohepatic
cycle maintain the plasma level. Decreased tissue folate
intake leads to diminished cellular folylpolyglutamate
synthesis and increased cellular transformation of
folylpolyglutamate, by hydrolysis, into monoglutamate
species. 5-MTHF-Glu1 is reabsorbed from the renal
proximal tubules via receptor-mediated endocytosis and
contributes to plasma 5-MTHF-Glu1 levels. Due to the
GGH enzyme in plasma, folylpolyglutamate is not found
in plasma (3).
Approximately 30%–40% of endogenous plasma folate
is attached to low-affinity proteins, especially albumin; other
proteins include alpha-2-macroglobulin and transferrin.
In folate deficiency, the bound folate increases. Plasma
also contains high-affinity folate-binding proteins in small
amounts. Their amounts increase in folate deficiency,
pregnancy, leukemia, and uremia. These proteins are
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found at high concentrations in blood obtained from the
umbilical cord. The high-affinity folate-binding proteins in
plasma are homologs of the folate-binding proteins found
at the cell membrane (4).
2.3.2. Transport in erythrocytes
During erythropoiesis in the bone marrow, folate is
found in growing erythroblasts. Most of the folate
in erythrocytes is in the form of 5-MTHF-Glun and
5-formyltetrahydrofolate (5-FTHF)-Glun (5). The normal
intraerythrocyte concentration is 190–650 ng/mL; in
deficiency, it is 150–189 ng/mL; and in insufficiency, it is
<150 ng/mL. There is no known role for erythrocyte folate,
but it is thought that this folate is involved in long-term
folate homeostasis and reserves. In contrast to plasma
concentrations, it is not affected by recently eaten foods.
Thus, measurement of erythrocyte folate can provide
information about long-term folate status. Folic acid in old
erythrocytes is rescued by the reticuloendothelial system
and then transported to the liver.
2.3.3. Cellular and intracellular transport
In plasma, folate monoglutamates are present in a
hydrophilic form with 2 valence anions at nanomolar
concentrations (6). For this reason, there is a need
for transport systems to operate against the more
concentrated intracellular medium. Folate transport is
also important for intracellular compartmentalization, not
just at the cell membrane (7). There are 3 physiological
mechanisms for transportation from the cell membrane.
The first is transport by the folate-binding proteins/folate
receptors (FRs) family, which moves folate into the cell
unidirectionally (8). FRs operate by receptor-mediated
endocytosis. They are held in the plasma membrane by a
glycosylinositol anchor and are largely limited to the apical
membrane of epithelial cells (9). They can bind various
folyl coenzymes with high affinity. The protein–folate
complex is taken inside the cell by a nonclathrin-mediated
endocytotic pathway without lysosomal function (10).
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Certain tissues are rich in the components of this transport
system, such as the choroid plexus, vas deferens, renal
proximal tubules, erythropoietic cells, ova, and placental
trophoblasts (11). The second mechanism is transport via
reduced folate carrier (RFC). Unlike receptor-mediated
transport, this allows bidirectional transportation.
The RFC serves as an anion exchanger that increases
intracellular folate concentrations (5). This is the major
folate uptake pathway in mammalian cells. In addition, this
transporter-mediated system is found in other subcellular
organelles, especially lysosomes and mitochondria (5).
This transporter-mediated process is more effective than
receptor-mediated transport (11). As a third mechanism,
it has been shown that there can be folate transportation
via passive diffusion across cell membranes (7).
Folate polyglutamate species with up to 4 glutamate
residues can be ejected from the cell in 3 different ways:
via multidrug resistance protein family members (MRPs/
ABCCs), breast cancer resistance protein family members
(BRCP/ABCG2), and RFCs. The first 2 are adenosine
triphosphate (ATP)-dependent and downregulated in
folate deficiency (12).
While folate transport to mitochondria occurs in
monoglutamate form, transport outside of the mitochondria
is carried out in both mono- and polyglutamate forms.
Monoglutamates that enter mitochondria can be converted
into polyglutamate forms by folylpolyglutamate synthase
(FPGS). How polyglutamates leave mitochondria remains
unclear (13).
Folate polyglutamates in the cytoplasm can enter
lysosomes via a transporter-mediated system, and there
they can be converted into monoglutamate forms, again by
GGH. However, it remains unknown how monoglutamyl
folates exit lysosomes and endosomes (13).
Folate enters a cell as 5-MTHF-Glu1 on a large scale. In
cells, the vitamin B12-dependent methionine synthase acts
as the rate-limiting step for the intracellular accumulation
of folate. At the same time, transformation of 5-MTHFGlu1 into tetrahydrofolate by vitamin B12-dependent
methionine synthase leads to the transformation of
dietary-origin 5-MTHFGlu1 into the biologically more
useful intracellular vitamin form, which can also be used
in nucleotide biosynthesis. This reaction is a unique step,
demethylating 5-MTHF-Glu1 into THF-Glu1 (13,14).
Folylpolyglutamates are generally better substrates
than monoglutamyl forms for folate-dependent enzymes
(15). Although the liver has the highest FPGS activity and
is the main folate depot, folate polyglutamylation occurs
in many different cell types. As oligo-gamma-glutamyl
chain length rises, Km values decrease. The oligo-gammaglutamyl chain that can be conjugated to folate provides
the cellular retention of folate, regulates the reaction rate,
and facilitates the participation of substrate in the reaction

(15). In mammalian cells, FPGS isoenzymes function
in both the cytosol and mitochondria. While cytosolic
FPGS is necessary to maintain the cytosolic folate pool,
mitochondrial FPGS is essential for the accumulation
of folate in mitochondria (16). Increased FPGS activity
increases the chain length of folate polyglutamate;
however, increased folate monoglutamate intake decreases
it, because of substrate competition (17). Cellular
retention of folate is also regulated by GGH. This enzyme
lets folate-monoglutamates exit from the cell by separating
polyglutamate peptides from polyglutamylfolates. GGH
exists in many tissues, especially in lysosomes (13).
2.4. Intracellular distribution of folate
Most cellular folate is held in intracellular compartments.
Almost half of it is located in mitochondria and a large
part of the rest is in the cytoplasm. Although folate exists
in other organelles, including the nucleus, these do not
make an important contribution to total cellular folate
concentrations (16).
Most cellular folate is attached to proteins.
Approximately 60% of cytoplasmic folate and 20% of
mitochondrial folate is tightly bound with proteins in rat
liver. Studies on cell cultures have shown that unbound or
free folate concentrations are negligible (18). The major
proteins that tightly bind intracellular folate in rat liver
include mitochondrial sarcosine and dimethylglycine
dehydrogenase, cytoplasmic glycine-N-methyltransferase
(19), and 10-formyltetrahydrofolate dehydrogenase. These
proteins are synthesized in large amounts in the liver,
which stores almost half of the total body folate (20).
Folate metabolism in cytoplasm is required for
de novo purine and pyrimidine synthesis, and for the
remethylation of homocysteine into methionine. In
addition, mitochondrial folate metabolism provides onecarbon units for cytoplasmic one-carbon metabolism in
the production of amino acids, as serine, glycine, sarcosine,
and dimethylglycine. Folate metabolism in the nucleus is
involved in the synthesis of dTMP and serine from dUMP.
3. Homocysteine and its metabolism
Homocysteine (2-amino-4-mercapto butyric acid) is a
sulfur-containing amino acid from a nonprotein source;
it is not included in the structure of any protein and is
synthesized from methionine. Homocysteine is oxidized
rapidly in plasma and thus it can be found in many forms.
Most of it is bound to albumin with a disulfide bond. The
rest is in unbound free disulfide and sulfhydryl forms (21).
Homocysteine exists at the junction point of 2 important
pathways and is regulated by many different enzymes
(Figure 2). The destiny of homocysteine, between de
novo methionine biosynthesis and the transsulfuration
pathway, is determined by S-adenosylmethionine (SAM)
allosterically (22).
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Figure 2. Folate and homocysteine metabolisms. DHFR, dihydrofolate reductase; SHMT, serine hydroxymethyl transferase;
MTHFR, methylene tetrahydrofolate reductase.

In the homocysteine remethylation cycle, at the
beginning, 5,10-methylene-THF is reduced to 5-MTHF
by 5,10-methylene tetrahydrofolate reductase (MTHFR).
This is a unique in vivo reaction that produces 5-MTHF.
Vitamin B12-dependent methionine synthase then
converts the homocysteine into methionine; in this
process, 5-MTHF is transformed into THF. This final step
requires methionine synthase reductase (MSR), which
activates the methionine synthase by reducing it. In
addition, homocysteine can be converted into methionine
by betaine-homocysteine methyltransferase (BHMT),
which is not dependent on vitamin B12. Subsequently,
synthesized methionine is transformed into SAM, which is
a general methyl donor for some important biomolecules,
such as adrenaline, phosphatidylcholine, and carnitine,
by methionine adenosyl transferase and ATP. The cycle
is then completed with the transformation of SAM into
S-adenosyl homocysteine (SAH), and later, back into
homocysteine.
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The transsulfuration of homocysteine involves uniting
with serine to produce cystathionine. This vitamin B6dependent reaction is catalyzed by cystathionine-βsynthase (CBS). After passing this step, homocysteine can
no longer be a precursor for methionine. Next, cystathionine
is hydrolyzed into cysteine and α-ketobutyrate by another
vitamin B6-dependent enzyme, cystathionine-γ-lyase
(CGL) (Figure 2).
In vitamin B12 functional deficiency, homocysteine and
methylmalonic acid (MMA) levels increase in plasma and
urine. Because folate is another coenzyme of methionine
synthase, MMA measurements are more selective for
vitamin B12 status alone (23).
4. Metabolic regulation of remethylation and
transsulfuration pathways
The transfer of one-carbon units that have important
roles in human biochemistry is executed generally with
SAM, synthesized from methionine. Methionine is
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supplied from exogenous sources, such as food, and from
homocysteine in the remethylation cycle, where 5methyl
THF and vitamin B12 are cofactors.
While SAM inhibits MTHFR, it activates CBS
allosterically. For this reason, when SAM levels decrease,
5-MTHF synthesis will be limited and cystathionine
formation will be reduced. In this case, homocysteine is
cannibalized for methionine production. In the opposite
condition, homocysteine is shifted to the transsulfuration
pathway. SAH limits its own synthesis by inhibiting SAMdependent methyltransferases, as well as by abolishing
MTHFR inhibition by SAM. In addition, both SAH and
methionine inhibit methionine synthase (22) (Table).
The SAM/SAH ratio, homocysteine concentration,
specific dietary factors (especially folate and methionine),
vitamin B12, and vitamin B6 are all important determinants
of one-carbon metabolism and the metabolic balance
between the remethylation and transsulfuration pathways
(2). Humans consume many more methyl groups than are
gained from dietary methionine. Betaine and 5-MTHF
compensate for this deficit. The cause of the continuous
SAM requirement is creatine formation, which consumes
more SAM than other transmethylation reactions. In
addition to the allosteric regulation of SAM, 5-MTHF also
has effects on methionine metabolism. If SAM production
from methyl groups from 5-MTHF is more than that from

dietary methionine, excess 5-MTHF inhibits glycine-Nmethyltransferase and thus SAM utilization (24).
5. Relationship between one-carbon metabolism and
neurological and neuropsychiatric disorders
The methylation process may play a central role in the
biochemical bases of neuropsychiatry. Folate and vitamin
B12 are independent and essential components of onecarbon metabolism (25). Deficiency in vitamin B12, which
is also a cofactor for methionine synthase, also leads to a
functional deficiency in folate and plays a role as another
cofactor of the same enzyme. On the other hand, low
folate concentrations cause reductions in neurotransmitter
synthesis, SAM synthesis, and the methylation of
phospholipids in neuronal membranes.
The most important result of these deficiencies, and
also the most suitable biochemical sign of functional
insufficiency of folate and vitamin B12, is elevated
homocysteine levels. Excess homocysteine released from
extrahepatic tissues that do not have the transsulfuration
pathway is taken up by the liver for remethylation into
methionine; in cases of pathological accumulation of
homocysteine, this can lead to homocysteinuria, or, in
some cases, reduced urinary excretion of homocysteine.
The nervous system is particularly sensitive to
extracellular homocysteine. Indeed, homocysteine has

Table. Metabolic regulation of remethylation and transsulfuration pathways*.

Enzyme

Km, µM

Intense tissues

MAT 1

3–41

MAT 2

Effects of metabolites
Methionine

SAM

L

S

P

4–23

Extrahepatic

S

P, I

SAHH

8–60

All tissues

MS

60

All tissues

MTHFR

---

All tissues

BHMT

2–60

L, K

MAT 3

30–1300

L

CBS

1000-25,000

L, K, B, Pa, SI

CGL

3000

L, K, Pa, SI

GNMT

30–180

L, K, Pa, SI

SAH

S
P, I

I
I

A

P, I

InA, DR

I

S

P, A
A

A

S, A

P, I

I

Abbreviations:
MAT: methionine adenosyl transferase, SAHH: S-adenosylhomocysteine hydrolase, MS: methionine synthase,
MTHFR: methylene tetrahydrofolate reductase, BHMT: betaine hydroxymethyl transferase, CBS: cystathionine-βsynthase, CGL: cystathionine-γ-lyase, GNMT: glycine-N-methyl transferase.
L: liver, K: kidney, B: brain, Pa: pancreas, SI: small intestine.
S: substrate, P: product, I: inhibitor, A: activator, InA: inactivator, DR: down-regulator at synthesis.
* Sources of data detailed by Finkelstein (24).
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neurotoxic and vasculotoxic effects (26–28), and is also
a risk factor for atherosclerosis, atherothrombosis, and
endothelial dysfunction (29,30). In fact, homocysteine can
be transformed into cystathionine via cystathionine-βsynthase activity; as a result of this cystathionine-β-synthase
action, the antioxidant glutathione can compensate for
potential oxidative damage from excess homocysteine
(31). Although there is no conversion of cystathionine
into cysteine in the brain, the conversion of homocysteine
into cystathionine does occur (32). Homocysteine causes
synaptic dysfunction and neuronal damage as a result of
metabolic effects (26,33,34), as follows.
• It is an agonist for NMDA calcium channels, causing
excitotoxicity and damaging neuronal DNA.
• It can start calcium efflux by having direct effects on
glutamate receptors.
• It can potentiate its own pathogenic effects by inducing
stress in the endoplasmic reticulum.
• It induces oxidative stress, leading to the formation of
reactive oxygen species.
• It can activate apoptotic signal cascades, such as P53
and Bax.
• It can cause cytochrome c release and caspase
activation.
Fetuses of pregnant women with dietary folate
deficiency are at risk for neural tube defects, such as spina
bifida, meningocele, encephalocele, and anencephaly (35).
Studies of cultured embryonic brain cells have shown that
folate-deprived astrocytes and neural stem cells inhibit
their own proliferations (33). In addition, methotrexate, an
inhibitor of folate metabolism, inhibits neural progenitor
cell proliferation and induces apoptosis in newly generated
neurons (36). During the infancy period, vitamin B12
deficiency results in psychomotor regression, sensorial
neuropathy, serious hypotonia, and apathy, all of which are
associated with impaired myelination (37,38).
The most common polymorphism on the MTHFR
gene is C677T. In homozygous individuals, there is mild
homocysteinemia that may increase with decreased
dietary folate intake (39). Genetic defects in MTHFR lead
to psychomotor growth delay, serious mental retardation,
and other psychiatric problems in infancy (40).
One-third of psychiatric and psychogeriatric patients
have low serum or erythrocyte folate levels (41,42).
Folate deficiency affects normal brain development by
different mechanisms (43). First, because folate is an
essential precursor for DNA synthesis, deficiency disrupts
the division of neural progenitor cells. Related to this,
in a study of pregnant mice, it was found that folate
deficiency disrupts the replication of progenitor cells in
the ventricular germinal zones of the brain where a large
proportion of cortical neurons begin to migrate (44).
Second, folate deficiency may affect normal fetal brain
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development because of elevated homocysteine levels
in the mother. During the third trimester of pregnancy,
maternal hyperhomocysteinemia is associated with a
2-fold increased risk for schizophrenia in babies (45).
5.1. Psychosis (schizophrenia)
A relationship between methylation and schizophrenia
was first established by Osmond and Smythies in 1952
(46). In that study, they hypothesized that methionine was
a methyl donor for the synthesis of hallucinogenic amines.
Further studies reported that folate deficiency was present
in only 25%–30% of schizophrenics (47). However, in
many studies, hyperhomocysteinemia has been the most
common finding, especially in young and first-episode
schizophrenia patients (48–50).
In addition, mean urine MMA levels may be significantly
higher in patients with psychosis and depression. Thus,
urine MMA measurements may provide more valuable
information than serum vitamin B12, and urine MMA
measurements can show whether vitamin B12 has entered
a cell (23). Another study showed that, in association with
one-carbon metabolism, although erythrocyte membrane
phosphatidylcholine concentrations were lower than in a
control group, phosphatidylethanolamine concentrations
were higher in schizophrenic patients because of impaired
phospholipid methylation (51).
5.2. Alzheimer’s disease
People who develop Alzheimer’s disease may have had
increased homocysteine levels earlier in life. Indeed,
elevated homocysteine is often considered an early sign of
cognitive impairment in geriatrics (52,53). There is also a
strong association between low folate concentrations and
cerebral cortex atrophy (54). In addition, although folate
levels are 3- to 4-fold higher in cerebrospinal fluid (CSF)
than in blood in healthy individuals, Alzheimer’s disease
patients have significantly low levels of CSF folate (55).
In addition, SAM concentrations are lower in the CSF of
Alzheimer’s disease patients compared to healthy controls
of the same mean age (56).
5.3. Autism
Approximately 20 years ago, health institutes recommended
folic acid support for pregnant women to protect against
neural tube defects (NTDs). Investigations have shown that
after folate supplementation, NTD incidence decreases by
approximately 70% and its clinical severity is also reduced
(57). However, as folic acid fortification has increased,
so has the incidence of autism, suggesting another
problem. In the United States, it has been reported that
the incidence of autism increased after folate fortification
(58,59). The Autism Genome Project Consortium noted
that the glutamatergic neural system and genes associated
with glutamate may contribute to the appearance of
autism spectrum disorders (60). Glutamate pathways play
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key roles in the development of the neural system, and
glutamatergic system disorders may cause autism (61). All
folate species contain at least one glutamate residue and
potentially facilitate the excitatory properties of glutamate
(61): they inhibit high-affinity glial uptake of glutamate,
compete with inhibitor neurotransmitters for binding to
receptors, and slow glutamate decarboxylase activity. The
kainic acid receptor is a subunit of glutamate receptor 6
and a mutation in the kainic acid receptor gene may be
associated with autism (62).
6. Conclusion
In spite of intensive research into neuropsychiatric
disorders, adequate explanations for their pathogenesis

and biochemical diagnostic markers are not available yet.
Psychiatric diagnosis is specifically based o
 n the behavioral
aspects. In these diseases, some evidence about disorders
of the one-carbon cycle regulation or folate metabolism
has begun to emerge. Although biomarkers of impaired
one-carbon metabolism show relationships at the level
of common findings in neuropsychiatric disorders, the
evidence is insufficient to establish a causal relationship.
However, once one-carbon metabolism dysregulation
is restored, significant improvements in symptoms
can be seen in these patients. Further investigations
into the relationships between one-carbon metabolism
and neuropsychiatric disorders could illuminate their
pathogenesis.
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